Statins: Drugs for Alzheimer's disease?

G. P. Eckert, W. G. Wood, W. E. Müller

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Evidences from cell culture experiments and animal studies suggest a strong link between cholesterol and Alzheimer's disease (AD). This relationship is supported by retrospective epidemiological studies demonstrating that statin treatment reduced the prevalence of AD in patients suffering from hypercholesterolaemia. The alternative processing of the amyloid-precursor protein (APP) in the brain of AD patients leads to the production of the neurotoxic amyloid-beta protein (Aβ), a causative factor for AD pathology. In vitro, this mechanism is modulated by alterations in cellular cholesterol levels. Moreover, lowering cholesterol in animal experiments reduced the production of Aβ in most but not all studies. These findings led to prospective clinical trials of cholesterol-lowering statins in AD patients, even if many studies do not support elevated cholesterol levels in serum and brain as a risk factor for Alzheimer's disease. Most of these studies were negative. Thus, up to date there is insufficient evidence to suggest the use of statins for treatment in patients with AD.

Original languageEnglish (US)
Pages (from-to)1057-1071
Number of pages15
JournalJournal of Neural Transmission
Issue number8
StatePublished - Aug 2005


  • Alzheimer's disease
  • Brain
  • Cholesterol
  • Statins


Dive into the research topics of 'Statins: Drugs for Alzheimer's disease?'. Together they form a unique fingerprint.

Cite this